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Coagulation is a host defense system that limits the spread of pathogens. Coagulation proteases, such as 
thrombin, also activate cells by cleaving PARs. In this study, we analyzed the role of PAR-1 in coxsackievirus 
B3–induced (CVB3-induced) myocarditis and influenza A infection. CVB3-infected Par1–/– mice expressed 
reduced levels of IFN-β and CXCL10 during the early phase of infection compared with Par1+/+ mice that result-
ed in higher viral loads and cardiac injury at day 8 after infection. Inhibition of either tissue factor or thrombin 
in WT mice also significantly increased CVB3 levels in the heart and cardiac injury compared with controls. 
BM transplantation experiments demonstrated that PAR-1 in nonhematopoietic cells protected mice from 
CVB3 infection. Transgenic mice overexpressing PAR-1 in cardiomyocytes had reduced CVB3-induced myo-
carditis. We found that cooperative signaling between PAR-1 and TLR3 in mouse cardiac fibroblasts enhanced 
activation of p38 and induction of IFN-β and CXCL10 expression. Par1–/– mice also had decreased CXCL10 
expression and increased viral levels in the lung after influenza A infection compared with Par1+/+ mice. Our 
results indicate that the tissue factor/thrombin/PAR-1 pathway enhances IFN-β expression and contributes 
to the innate immune response during single-stranded RNA viral infection.
Introduction
Coagulation is an ancient host defense system in invertebrates 
and vertebrates that limits the spread of pathogens (1–6). In verte-
brates, the clotting system is composed of activators, such as the 
transmembrane protein tissue factor (TF), coagulation proteases, 
such as thrombin, and the final product, crosslinked fibrin (7). 
In addition, coagulation proteases can activate cells by cleavage 
of PARs (8–10). Bacterial and viral infections induce TF expres-
sion on various cell types, including monocytes and endothelial 
cells (11–20). Bacterial LPS induces TF expression in monocytes 
and endothelial cells via activation of TLR4 (21–23), whereas the 
TLR3 agonist polyinosinic:polycytidylic acid (poly I:C) induces TF 
expression in endothelial cells, but not monocytes (17). Uncon-
trolled TF-dependent activation of coagulation during infection 
leads to disseminated intravascular coagulation (13, 24–26). Fibrin 
has been shown to contribute to the innate immune response to 
bacterial infections by increasing the expression of inflammatory 
mediators (5, 27). In addition, PAR-1 expression is increased in 
endothelial cells after viral infection (16, 28). Interestingly, studies 
with cultured endothelial cells found that TF, thrombin, PAR-1, 
and PAR-2 contribute to the infectivity of the DNA virus herpes 
simplex virus type 1 (29, 30). Thrombin is the major activator of 
PAR-1, and this leads to the activation of numerous intracellular 
signaling pathways, including MAPK pathways (31, 32). Interest-
ingly, PAR-1 contributes to the proliferation of cardiac fibroblasts 
(CFs) and the hypertrophy of cardiomyocytes (33–35). In addition, 
we and others have shown that PAR-1 plays a role in cardiac injury 
and remodeling after ischemia-reperfusion injury (9, 36, 37).
The innate immune response is the first line of defense against 
pathogens (38). TLRs are a family of receptors that play a central 
role in host defense by recognizing pathogen-associated molecu-
lar patterns (PAMPs) (38). Viral infections are detected by dif-
ferent pattern recognition receptors (PRRs), including TLR3, 
retinoic acid–inducible gene I (RIG-I) protein, and melanoma 
differentiation–associated gene–5 (MDA-5) (39, 40). These sen-
sors are activated by double-stranded RNA (dsRNA), which is 
generated as a byproduct of single-stranded RNA (ssRNA) viral 
replication (39, 41). Poly I:C is used as a dsRNA mimetic and 
induces the binding of the adaptor protein Toll/IL-1 receptor/
resistance domain containing adaptor–inducing IFN-β (TRIF) 
to TLR3 homodimers on the cell surface or in endosomes. Sub-
sequently, there is activation of various signaling pathways and 
transcription factors, including tank binding kinases–1 (TBK-1), 
IFN regulatory factor–3 (IRF-3), the p38 and JNK MAPKs, and 
NF-κB (39). TLR3 signaling induces the expression of IFNs, 
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which initiate early innate immune responses to viruses (42, 43). 
IFNs are divided into type I (IFN-α and IFN-β), type II (IFN-γ), 
and type III (IFN-λ). Ifnb1 gene expression requires the activation 
of various intracellular signaling pathways, including the JNK 
and p38 MAPKs and the transcription factors AP-1, NF-κB, and 
IRF-3 (42, 44). Furthermore, TLR3-mediated p38 MAPK activa-
tion stabilizes Ifnb1 mRNA (45).
Infections with cardiotropic viruses, such as the ssRNA virus 
coxsackievirus B3 (CVB3), can result in myocarditis, dilated car-
diomyopathy, and heart failure (46). Although the virus is directly 
responsible for some organ injury, the majority of the injury is 
caused by the host inflammatory response to the virus (46). TLR3 
or TRIF deficiency is associated with increased viral titers and a 
higher mortality after infection with CVB3 or CVB4 (47–49). Type 
I IFN signaling, but not type II IFN signaling, is required for an 
innate immune response to CVB3 infection (50). Indeed, IFN-β–
deficient mice are more susceptible than WT mice to infection 
with CVB3 (51). Importantly, administration of IFN-α or IFN-β 
reduces CVB3-induced myocarditis in mice and humans (48, 52, 
53). Similarly, the ssRNA virus influenza A activates both TLR3 
and RIG-I in lung epithelial cells (54). IFN-α and -β are expressed 
at low levels by numerous cell types, such as CFs, cardiomyo-
cytes, and epithelial cells, and are induced in virus-infected cells 
to reduce viral replication (43, 55). IFNs induce the expression of 
various chemokines, such as CXCL10 (also called IP-10), and mice 
lacking CXCL10 have increased cardiac injury after CVB3 infec-
tion (56, 57). One role of CXCL10 is to recruit NK cells and CD3+ 
leukocytes to the site of infection to prevent the spread of infec-
tion by removing virally infected cells (56, 57).
TLRs and PARs have been proposed to act as a dual-sensor sys-
tem to detect infection: TLRs are activated by PAMPs, and PARs are 
activated by proteases, including coagulation proteases (58). Oth-
ers have proposed that PARs play roles in both innate and adaptive 
immunity (59, 60). The majority of studies have focused on PAR-
2. An early study reported that PAR-2 enhanced TLR4 signaling 
in macrophages and epithelial cells (61), whereas a more recent 
study found that activation of PAR-2 in primary mouse macro-
phages reduced LPS induction of proinflammatory cytokines and 
increased the expression of the antiinflammatory cytokine IL-10 
(62). In addition, PAR-2 was shown to suppress TLR3 signaling 
in lung epithelial cells, and PAR-2–deficient mice were protected 
against influenza A infection (63). However, a second study found 
that PAR-2–dependent expression of IFN-γ protected mice against 
influenza A infection (64). To date, the role of PAR-1 in the innate 
Figure 1
CVB3 levels and the early innate immune response in hearts of Par1+/+ (white symbols and bars) and Par1–/– (black symbols and bars) mice. (A) 
Levels of CVB3 genomes at different times after CVB3 infection. (B) CVB3 virus titers at 8 dpi. (C–E) Levels of Ifnb1 mRNA (C), Cxcl10 mRNA 
(D), and CXCL10 protein (E) expression before infection and at 2 or 4 dpi. (F and G) Levels of the NK cell–specific mRNA Nk1.1 (F) and number 
of CD3+ cells (G) at 4 dpi. Nk1.1 mRNA expression is shown relative to the level in infected Par1+/+ hearts. Representative images are shown. 
Arrows indicate staining of CD3+ cells. Scale bar: 100 μm. Data (mean ± SEM; n = 4–10 per group) were analyzed by 2-way ANOVA (A–E) or 
2-tailed Student’s t test (F and G). *P < 0.05; #P < 0.05 vs. respective genotype at day 0.
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immune response to ssRNA viral infection has not been studied 
in mice. Here, we investigated the role of PAR-1 in CVB3-induced 
myocarditis and influenza A infection.
Results
Par1–/– mice have increased levels of CVB3 in the liver and heart. CVB3 
infection of C57BL/6 mice leads to viral infection and replication 
in primary sites, such as the liver, at 2–4 days post infection (dpi), 
followed by secondary infection of the heart, with maximal levels 
of viral genomes observed at 8 dpi (65). Therefore, we measured 
levels of CVB3 in livers and hearts of Par1+/+ and Par1–/– mice at 
various times after infection. Mice were infected at 6–8 weeks of 
age via i.p. injection of 1 × 105 PFU purified CVB3 and analyzed 
at 2, 4, 8, and 28 dpi. These time points were chosen to investi-
gate the 3 phases of myocarditis: early (2–4 dpi; early viral replica-
tion), acute (8 dpi; maximal viral infection and cellular infiltra-
tion into the heart), and chronic (28 dpi; viral clearance and heart 
dysfunction) (65). Par1–/– mice had significantly higher levels of 
virus in the liver than did Par1+/+ mice at 8 dpi (Supplemental Fig-
ure 1A; supplemental material available online with this article; 
doi:10.1172/JCI66125DS1). In the heart, we observed significantly 
more CVB3 genomes and active virus in Par1–/– versus Par1+/+ mice 
at 8 dpi (Figure 1, A and B). No difference between genotypes was 
observed in the heart at 4 or 28 dpi (Figure 1A).
Par1–/– mice have reduced Ifnb1 and CXCL10 expression at 2 and 4 
dpi. We speculated that the increased levels of CVB3 genomes 
in Par1–/– mice may be due to reduced virus killing caused by 
reduced expression of the IFN-β/CXCL10 antiviral pathway. 
This pathway has been shown to play a central role in protect-
ing mice against CVB3 infection (50, 51, 56, 57). Therefore, we 
measured the levels of Ifnb1 mRNA expression and 
the IFN response gene CXCL10 in the heart before 
and after CVB3 infection. We observed lower levels of 
Ifnb1 mRNA expression in the hearts of Par1–/– com-
pared with Par1+/+ mice at 2 dpi (Figure 1C). Similarly, 
Par1–/– hearts had lower levels of Cxcl10 mRNA and 
CXCL10 protein expression at 4 dpi compared with 
Par1+/+ hearts (Figure 1, D and E). Levels of CXCL10 
expression were also significantly reduced in the liv-
ers of Par1–/– compared with Par1+/+ mice (Supple-
mental Figure 1B). Since CXCL10 recruits NK cells 
and CD3+ leukocytes into infected organs (56, 66), 
we analyzed early infiltration of these cells into the 
hearts of infected Par1+/+ and Par1–/– mice. At 4 dpi, 
hearts of Par1–/– mice had significantly lower levels 
of Nk1.1 mRNA, which is expressed by NK cells, and 
lower numbers of CD3+ cells compared with Par1+/+ 
mice (Figure 1, F and G).
Par1–/– mice have increased inflammation in the heart at 8 dpi. CVB3 
infection leads to inflammation and infiltration of immune 
cells into the heart (14). We hypothesized that the higher level 
of CVB3 at 8 dpi observed in Par1–/– mice will evoke a higher 
level of inflammation and infiltration of immune cells. We 
analyzed infiltration of immune cells into the hearts of CVB3-
infected Par1+/+ and Par1–/– mice by H&E and staining for CD68, 
and inflammation was assessed by measuring levels of various 
cytokine mRNAs. As expected, Par1–/– hearts had higher levels 
of inflammatory cell infiltrates and CD68+ cells than did Par1+/+ 
hearts at 8 dpi (Figure 2A). In addition, levels of Il1b, Il6, and 
Tnfa mRNA expression were significantly higher in Par1–/– versus 
Par1+/+ hearts at 8 dpi (Figure 2B).
Par1–/– mice have increased cardiac injury and dysfunction at 8 dpi. 
CVB3-induced myocarditis leads to cardiac injury and heart 
failure (14). We used plasma cardiac troponin I as a measure 
of cardiac injury. Levels of plasma cardiac troponin I increased 
at 4 dpi and peaked at 8 dpi in both Par1+/+ and Par1–/– mice 
(Figure 3A). However, Par1–/– mice had significantly higher lev-
els of cardiac troponin I than did Par1+/+ mice at 8 dpi (Figure 
3A). Next, we measured cardiac hypertrophy by assessing heart 
weight/BW (HW/BW) ratios and dilation of the LV by echocar-
diography before CVB3 infection and at 28 dpi. Heart function 
was measured by examining the change in percent fractional 
shortening (FS) of the hearts, which was calculated from ven-
tricle dimensions assessed by echocardiography (Table 1). We 
observed a significant increase in HW/BW ratio in Par1–/–, but 
not Par1+/+, mice (Figure 3B). CVB3 infection also significantly 
increased cardiac hypertrophy and significantly decreased heart 
function in both Par1+/+ and Par1–/– mice (Figure 3, C and D). 
Figure 2
Inflammation in the hearts of CVB3-infected Par1+/+ and 
Par1–/– mice. (A) Levels of cellular infiltrates and CD68+ 
cells in Par1+/+ (white bars) and Par1–/– (black bars) hearts 
at 8 dpi. Representative images are shown. Arrows indicate 
areas of inflammatory cells (top) and CD68+ cells (bottom). 
Scale bars: 100 μm. (B) Inflammatory mediators in Par1+/+ 
and Par1–/– hearts at 8 dpi. Results are shown relative to 
mRNA expression level in infected Par1+/+ hearts. Data 
(mean ± SEM; n = 4–10 per group) were analyzed by 2-tailed 
Student’s t test. *P < 0.05.
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However, there was a significantly larger dilation of the LV and 
a significantly greater decrease in heart function in infected 
Par1–/– versus Par1+/+ mice (Figure 3, C and D).
Role of PAR-1 expression by hematopoietic and nonhematopoietic cells 
in CVB3-induced myocarditis. To analyze the role of PAR-1 on either 
hematopoietic or nonhematopoietic cells in CVB3 infection, we 
performed BM transplantation experiments. Irradiated Par1+/+ and 
Par1–/– mice were transplanted with either Par1+/+ or Par1–/– BM to 
create 4 chimeric groups of mice. As expected, there were signifi-
cantly higher levels of CVB3 genomes and plasma cardiac troponin 
I in the Par1–/– BM→Par1–/– transplant group than in the Par1+/+ 
BM→Par1+/+ group at 8 dpi (Figure 4, A and B). Par1–/– BM→Par1+/+ 
mice (with PAR-1 deficiency in hematopoietic cells) had a slightly 
higher level of CVB3 genomes than did Par1+/+ BM→Par1+/+ mice, 
whereas Par1+/+ BM→Par1–/– mice (with PAR-1 deficiency in non-
hematopoietic cells) had slightly higher levels of CVB3 genomes 
than did Par1–/– BM→Par1–/– mice (Figure 4A). We next assessed 
cardiac injury and found slightly higher cardiac tro-
ponin I levels in Par1–/– BM→Par1+/+ than in Par1+/+ 
BM→Par1+/+ mice, whereas cardiac troponin I 
levels of Par1+/+ BM→Par1–/– mice were intermedi-
ate between the Par1–/– BM→Par1–/– and Par1+/+ 
BM→Par1+/+ control groups (Figure 4B). These 
results suggest that PAR-1 on nonhematopoietic 
cells plays a more important role in CVB3 infection 
than PAR-1 on hematopoietic cells. The differences 
between CVB3 genomes and cardiac troponin I lev-
els may indicate different roles for PAR-1 in viral 
infection versus cardiac injury.
Mice overexpressing PAR-1 on cardiomyocytes are pro-
tected from CVB3-induced myocarditis. Previously, we 
generated αMHCPAR-1 mice, which overexpress 
PAR-1 on cardiomyocytes using the α–myosin 
heavy chain (αMHC) promoter (36). We hypoth-
esized that these mice may be protected from 
CVB3-induced myocarditis. αMHCPAR-1 mice and 
littermate WT controls were infected with CVB3, 
and CXCL10 expression as well as levels of viral 
genomes and inflammation were measured at 4 and 8 dpi. We 
found that αMHCPAR-1 mice had significantly increased CXCL10 
expression in the heart at 4 dpi compared with littermate controls 
(Figure 5A). Furthermore, αMHCPAR-1 mice had decreased levels 
of virus in the heart, but not in the liver, at 8 dpi compared with 
WT mice (Figure 5, B and C). The decrease in virus in the hearts 
of αMHCPAR-1 mice was associated with a significant reduction 
in inflammatory cell infiltrates in the heart, Tnfa mRNA expres-
sion, and cardiac injury compared with WT littermates at 8 dpi 
(Figure 5, D–F). Levels of Il1b and Il6 mRNA were also reduced in 
the hearts of αMHCPAR-1 mice compared with littermates (Fig-
ure 5E). These results indicate that overexpression of PAR-1 on 
cardiomyocytes protects mice against CVB3-induced myocarditis.
Role of TF and thrombin in CVB3-induced myocarditis. Virus infection 
is associated with TF-dependent activation of coagulation and the 
generation of thrombin, the major activator of PAR-1 in vivo (12–17). 
Previously, we found that TF protein expression was increased in 
Figure 3
Cardiac injury and function in Par1+/+ and Par1–/– mice 
after CVB3 infection. (A) Cardiac troponin I levels in 
plasma of Par1+/+ (white bars) and Par1–/– (black bars) 
mice before and at different time points after CVB3 
infection. (B) HW/BW ratios before infection and at 
28 dpi. (C) Echocardiographic analysis of systolic LV 
internal diameter (LVID-s) and (D) FS before infection 
and at 28 dpi. Data (mean ± SEM; n = 5–9 per group) 
were analyzed by 2-way ANOVA. *P < 0.05; #P < 0.05, 
##P < 0.01 vs. respective genotype at day 0.
Table 1
Heart function analysis by echocardiography before CVB3 infection and at 28 dpi
 Before infection 28 dpi
 Par1+/+ Par1–/– Par1+/+ Par1–/–
LVID-d (mm) 2.68 ± 0.11 2.52 ± 0.07 2.50 ± 0.07 2.74 ± 0.18
LVID-s (mm) 0.92 ± 0.09 1.00 ± 0.11 1.39 ± 0.05A 1.84 ± 0.19B,C
LVPW-d (mm) 1.29 ± 0.05 1.29 ± 0.07 0.91 ± 0.05B 0.90 ± 0.06B
LVPW-s (mm) 1.74 ± 0.04 1.64 ± 0.08 1.26 ± 0.07B 1.21 ± 0.05B
LVAW-d (mm) 1.26 ± 0.05 1.25 ± 0.03 0.99 ± 0.05B 1.04 ± 0.06A
LVAW-s (mm) 1.69 ± 0.05 1.68 ± 0.05 1.39 ± 0.06B 1.40 ± 0.05A
LV vol-d (μl) 27.19 ± 2.75 23.11 ± 1.75 21.92 ± 1.62 30.35 ± 5.52
LV vol-s (μl) 4.18 ± 0.45 3.77 ± 0.46 5.31 ± 0.50 11.28 ± 3.24A,C
EF (%) 84.71 ± 1.30 83.97 ± 1.01 79.12 ± 1.31 69.61 ± 3.24A,C
FS (%) 52.27 ± 1.47 51.04 ± 1.10 45.97 ± 1.33A 38.24 ± 2.27B,C
-d, diastolic; -s systolic; LVID, LV internal diameter; LVPW, LV posterior wall thickness; 
LVAW, LV anterior wall thickness; LV vol, LV volume; EF, ejection fraction. Data (mean 
± SEM; n = 5–9 per group) were analyzed by 2-way ANOVA. AP < 0.05, BP < 0.01 vs. 
respective genotype before infection; CP < 0.05 versus 28 dpi Par1+/+.
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the hearts of CVB3-infected WT mice at 8 dpi, and this was asso-
ciated with increased fibrin deposition (14). In this study, we ana-
lyzed levels of Tf mRNA expression in the heart and the activation 
of coagulation in the circulation of WT mice at different times after 
CVB3 infection. We used levels of plasma thrombin-antithrombin 
(TAT) complexes as a marker of activation of coagulation. We found 
that Tf mRNA expression was transiently induced in the heart, with 
maximal levels at 4 dpi (Figure 6A). Tf mRNA expression was also 
increased in the liver of CVB3-infected mice at 4 dpi (Supplemental 
Figure 1C). We observed a significant increase in plasma TAT levels 
at 4 and 8 dpi (Figure 6B). Next, we analyzed fibrin deposition in 
the hearts of CVB3-infected mice. Fibrin was observed in the myo-
cardium adjacent to areas of infiltrating immune cells (Figure 6C).
To investigate the role of TF in CVB3-induced myocarditis, 
WT mice were given either a rat anti-mouse TF-inhibitory 
monoclonal antibody (1H1; 20 mg/kg) or a rat IgG2a (20 mg/kg) 
via i.p. injection 1 day before CVB3 infection and at 2 and 5 
dpi (67), then euthanized at 8 dpi. We found that inhibition of 
TF significantly increased levels of CVB3 genomes and cardiac 
injury compared with uninhibited controls (Figure 7, A and 
B). Next, we determined the effect of inhibiting thrombin on 
CVB3-induced myocarditis by feeding WT mice an AIN-93M 
chow diet containing peanut flavoring with or without dabi-
gatran etexilate (10 g/kg chow) for 7 days prior to CVB3 infec-
tion and at 8 dpi. The level of anticoagulation was assessed by 
measuring the activated partial thromboplastin time (aPTT) in 
both groups. Mice fed the dabigatran etexilate diet had signifi-
cant aPTT prolongation compared with mice fed a placebo diet 
(25.00 ± 0.97 vs. 68.15 ± 7.11 seconds; P < 0.001). We found that 
inhibition of thrombin significantly increased viral genomes 
in the hearts and cardiac injury at 8 dpi compared with WT 
mice that received normal chow (Figure 7, C and D). These 
results indicate that both TF and thrombin play a role in CVB3-
induced myocarditis.
Thrombin not only activates PAR-1, but also activates PAR-4 and 
cleaves fibrinogen. To determine whether thrombin has effects 
beyond simply activating PAR-1, we compared the effect of inhib-
iting thrombin in Par1–/– and Par1+/+ mice. We found that Par1–/– 
mice had significantly higher levels of CVB3 genomes and cardiac 
injury than did thrombin-inhibited Par1+/+ mice (Figure 7, E and 
Figure 4
Cellular sources of PAR-1 that contribute to protection from CVB3-induced myocarditis. CVB3 genomes in the heart (A) and cardiac injury (B) in 
CVB3-infected control Par1+/+ BM→Par1+/+ and Par1–/– BM→Par1–/– chimeric mice, Par1–/– BM→Par1+/+ mice (PAR-1 deficiency in hematopoietic 
cells), and Par1+/+ BM→Par1–/– mice (PAR-1 deficiency in nonhematopoietic cells) at 8 dpi. Data (mean ± SEM; n = 4–10 per group) were analyzed 
by 2-way ANOVA. *P < 0.05.
Figure 5
Overexpression of PAR-1 reduces 
CVB3-induced myocarditis. WT 
(white) and αMHCPAR-1 (gray) 
animals were infected with CVB3. 
(A) CXCL10 protein levels in 
heart at 4 dpi. (B and C) Number 
of CVB3 genomes in heart (B) 
and liver (C) at 8 dpi. (D) Levels 
of inflammatory cell infiltrates in 
heart at 8 dpi. (E) Il1b, Tnfa, and 
Il6 mRNA expression in heart at 
8 dpi. mRNA expression for each 
gene is shown relative to WT. (F) 
Circulating cardiac troponin I at 8 
dpi. Data (mean ± SEM; n = 4–9 
per group) were analyzed by 2-way 
ANOVA (A) or 2-tailed Student’s 
t test (B–F). *P < 0.05; #P < 0.05 vs. 
respective genotype at day 0.
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F). Surprisingly, inhibition of thrombin in Par1–/– mice reduced 
levels of CVB3 genomes and cardiac troponin I compared with 
Par1–/– mice fed normal chow (Figure 7, E and F).
Stimulation of PAR-1 on cardiac fibroblasts enhances TLR3 activation of 
p38 and induction of IFN-β and CXLC10 expression. Viral infection of 
CFs and cardiomyocytes induces IFN-β expression (55). In addi-
tion, stimulation of mouse CFs with the TLR3 agonist poly I:C 
induces Ifnb1 mRNA and CXCL10 protein expression (40). Our 
BM transplantation experiments indicated that PAR-1 on non-
hematopoietic cells plays a role in CVB3-induced myocarditis. 
Although CFs and cardiomyocytes both express PAR-1 (35), CFs 
are easier than cardiomyocytes to isolate and maintain in culture. 
Therefore, we examined the effect of PAR-1 activation on poly I:C 
induction of Ifnb1 mRNA and CXCL10 expression in Par1+/+ CFs. 
Time course experiments showed that poly I:C stimulation led to 
maximal Ifnb1 mRNA expression at 2 hours and maximal CXCL10 
protein expression at 8 hours (data not shown). TLR3 is generally 
present in endosomes, but can also be expressed on the cell sur-
face (39). To confirm that TLR3 was mediating the induction of 
CXCL10 expression, we used various inhibitors of TLR3 signaling. 
Clathrin-dependent endocytotic uptake of poly I:C was inhibited 
with monodansylcadaverine (MDC; 60 μM), endosomal acidifica-
tion was inhibited with chloroquine (100 μM), and TBK-1 activa-
tion was inhibited with BX795 (1 μM). All 3 inhibitors reduced 
poly I:C induction of CXCL10 in WT CFs by 70%–100% (data 
not shown). Taken together, these results indicated that poly I:C 
induction of CXCL10 is primarily mediated by TLR3.
Previous studies have shown that stimulation of PAR-1 activates 
p38 (32). Furthermore, p38 is required for dsRNA-dependent 
induction of CXCL10 (68). Therefore, we analyzed the activation 
of p38 in CFs treated with poly I:C and/or a PAR-1 agonist peptide. 
We found that activation of PAR-1 in Par1+/+ CFs led to a small 
but significant transient phosphorylation of p38 between 15 and 
60 minutes (Figure 8A). As expected, no response was observed 
in Par1–/– CFs. Stimulation of Par1+/+ or Par1–/– cells with poly I:C 
led to slower phosphorylation of p38, with the highest levels at 
120 minutes, but no significant differences were observed between 
Par1+/+ and Par1–/– CFs (Figure 8A). Importantly, we observed a sig-
nificant difference in the level of p38 phosphorylation between 
Par1+/+ and Par1–/– CFs stimulated with poly I:C and agonist 
peptide (Figure 8A). In addition, there was a significant difference 
in p38 phosphorylation in Par1+/+ cells treated with poly I:C alone 
Figure 6
TF expression, TAT levels, and fibrin deposition in the hearts of infected WT mice. Tf mRNA expression (A), plasma TAT levels (B), and fibrin(ogen) 
staining (C) in control and CVB3-infected WT hearts. Arrows indicate fibrin staining (brown); arrowheads indicate inflammatory cell infiltrates. 
Scale bar: 100 μm. Data (mean ± SEM; n = 4–14 per group) were analyzed by 1-way ANOVA. #P < 0.05 vs. day 0.
Figure 7
Effect of inhibition of TF or thrombin 
on CVB3-induced myocarditis. (A–D) 
TF inhibition (A and B) and thrombin 
inhibition (C and D) both increased lev-
els of CVB3 genomes (A and C) and 
cardiac injury (B and D) in WT mice at 
8 dpi. Data (mean ± SEM; n = 4–10 per 
group) were analyzed by 2-tailed Stu-
dent’s t test. (E and F) Thrombin inhi-
bition increased CVB3 genomes and 
cardiac injury in Par1+/+ mice (white 
bars), but reduced CVB3 genomes 
and cardiac injury in Par1–/– mice (black 
bars). Data (mean ± SEM; n = 10–23 
per group) were analyzed by 2-way 
ANOVA. *P < 0.05; #P < 0.05 vs. Par1+/+ 
control; †P < 0.05 vs. Par1–/– control.
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versus poly I:C and agonist peptide (P = 0.017). These results indi-
cated that stimulation of PAR-1 significantly increased the activa-
tion of p38 in poly I:C–stimulated cells.
To directly analyze Ifnb1 gene transcription, we used HEK-293 
cells expressing TLR3 and a plasmid containing the Ifnb1 pro-
moter cloned upstream of the secreted alkaline phosphatase 
(SEAP) reporter gene. Stimulation of the cells with 200 μM ago-
nist peptide, but not 100 μM, increased a small amount of SEAP 
expression in the culture media (Figure 8B). Poly I:C stimula-
tion of the cells produced a more pronounced increase in SEAP 
expression (Figure 8B). We found that SEAP expression in poly 
I:C–stimulated cells was increased in a dose-dependent manner by 
activation of PAR-1 (Figure 8B). Next, we determined the effect of 
PAR-1 stimulation on poly I:C induction of Ifnb1 mRNA expres-
sion in CFs. Poly I:C alone induced the expression of Ifnb1 mRNA 
expression, whereas agonist peptide alone had no effect (Figure 
8C). Importantly, agonist peptide significantly enhanced TLR3-
dependent induction of Ifnb1 mRNA expression in Par1+/+ CFs but 
not in Par1–/– CFs (Figure 8C). We examined the role of p38 in the 
induction of Ifnb1 mRNA expression in Par1+/+ and Par1–/– CFs by 
treating the cells with the p38 inhibitor SB203580 (69). Inhibi-
tion of p38 significantly reduced Ifnb1 mRNA expression in both 
Par1+/+ and Par1–/– CFs stimulated with poly I:C alone or with poly 
I:C and agonist peptide (Figure 8C). In contrast, inhibition of 
Figure 8
Effect of PAR-1 activation on poly I:C activation of p38 and induction of Ifnb1 mRNA expression. (A) Levels of phosphorylated p38 in Par1+/+ and 
Par1–/– CFs before and after stimulation with 200 μM agonist peptide (AP) and/or 25 μg/ml poly I:C for the indicated times. Phosphorylated p38 
levels (normalized to GAPDH) are shown relative to unstimulated Par1+/+ cells. Representative Western blots are also shown. (B) Levels of SEAP 
in the culture media of HEK-293 cells stimulated with 25 μg/ml poly I:C and/or 100 or 200 μM agonist peptide for 24 hours. Data are shown from 
12 independent samples per group. (C) Ifnb1 mRNA expression in Par1+/+ (white bars) and Par1–/– (black bars) CFs before and after stimulation 
with 25 μg/ml poly I:C and/or 200 μM agonist peptide for 2 hours. Results are shown relative to poly I:C–stimulated Par1+/+ CFs. The p38 inhibitor 
SB203580 (SB; 10 μM) was added 30 minutes prior to poly I:C stimulation. Data (mean ± SEM; n = 5–9 independent experiments) were analyzed 
by linear mixed models with a random intercept (A) or by 1-way (B) or 2-way (C) ANOVA. *P < 0.05, Par1+/+ vs. Par1–/–; #P < 0.05 vs. unstimulated 
control within the same genotype; †P < 0.05 versus poly I:C alone within the same genotype; §P < 0.05 vs. poly I:C and agonist peptide.
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MEK1/2 with 10 μM PD98059 (69) had no effect on the induction 
of Ifnb1 mRNA with poly I:C alone or with agonist peptide (data 
not shown). These results indicated that p38 activation is required 
for both poly I:C induction of CXCL10 and agonist peptide–
dependent enhancement of Ifnb1 mRNA expression.
IFN-β binds to the type I IFN receptor on fibroblasts and induces 
CXCL10 expression via activation of the transcription factor STAT1 
(70). As expected from the results with Ifnb1 mRNA expression, 
Par1+/+ cells costimulated with both poly I:C and agonist peptide 
expressed higher levels of phosphorylated STAT1 than did Par1+/+ 
cells stimulated with poly I:C alone (Figure 9A), which indicates 
that the costimulated cells released more IFN-β. Similar results were 
observed with adult mouse Par1+/+ CFs (data not shown). To con-
firm that there was no defect in IFN-β signaling in Par1–/– CFs, we 
compared the level of phosphorylated STAT1 in Par1+/+ and Par1–/– 
CFs stimulated with recombinant IFN-β. We found that recombi-
nant IFN-β induced a similar level of STAT1 phosphorylation at 30 
minutes in Par1+/+ and Par1–/– CFs and that the phosphorylation was 
not increased by agonist peptide (Figure 9B). These results indicated 
that Par1–/– CFs have a deficiency in the induction of Ifnb1 mRNA 
expression, but not in IFN receptor signaling.
Poly I:C stimulation of Par1+/+ and Par1–/– CFs induced CXCL10 
expression, and this was significantly enhanced in Par1+/+ CFs, but 
not Par1–/– CFs, by activation of PAR-1 (Figure 9C). CXCL10 expres-
sion was also significantly reduced by inhibition of p38 (Figure 
9C). Interestingly, poly I:C–stimulated Par1–/– CFs expressed less 
CXCL10 at 8 hours compared with poly I:C–treated Par1+/+ CFs 
(Figure 9C). We recently showed that stimulation of Par1+/+ CFs 
with isoproterenol induced the release of MMPs that activate PAR-1 
(71). Therefore, we examined whether MMP activation of PAR-1 
increases CXCL10 induction in Par1+/+ CFs stimulated with poly 
I:C. Par1+/+ CFs were stimulated with poly I:C in the absence or pres-
ence of the MMP13 inhibitor WAY170523, the pan-MMP inhibitor 
GM6001, or the PAR-1 antagonist SCH79797. Blockade of MMPs 
or PAR-1 significantly reduced poly I:C induction of CXCL10 (Fig-
ure 9D). These results indicate that poly I:C–stimulated CFs release 
MMPs that activate PAR-1, which enhances CXCL10 expression.
PAR-1 deficiency is associated with increased viral load and inflammation 
after influenza A infection. Recent studies have shown that influenza 
A infections lead to a TLR3-dependent innate immune response, 
activation of coagulation, and an increase in PAR-1 expression 
in the lung (72, 73). To determine whether PAR-1 plays a role in 
the innate immune response to a different virus, we examined the 
effect of PAR-1 deficiency on infection with the ssRNA virus HA 
type 1 and neuraminidase type 1/Puerto Rico strain 8/34 (H1N1/
PR8) influenza A. Mice were infected i.n. with 50 μl of 2 hemagglu-
tinating units of H1N1/PR8 virus diluted in PBS. We found that 
Par1–/– mice expressed lower levels of lung CXCL10 and higher 
levels of H1N1/PR8 viral genomes compared with Par1+/+ mice at 
3 dpi (Figure 10, A and B). Furthermore, at 3 dpi, Par1–/– mice had 
higher levels of proinflammatory cytokines and chemokines in the 
BAL fluid than did Par1+/+ mice (Figure 10, C–F). These results sug-
gest that PAR-1 also plays a role in the innate immune response to 
influenza A infection.
Figure 9
Effect of PAR-1 activation on poly I:C activation of STAT1 and CXCL10 expression. (A) Levels of phosphorylated STAT1 in unstimulated or stimu-
lated (25 μg/ml poly I:C with or without 200 μM agonist peptide for 2 hours) Par1+/+ CFs. STAT1 phosphorylation levels (normalized to GAPDH) 
are shown relative to unstimulated Par1+/+. (B) STAT1 phosphorylation in Par1+/+ and Par1–/– CFs treated with 125 ng/ml recombinant IFN-β with 
or without 200 μM agonist peptide for 30 minutes. (C) CXCL10 expression in Par1+/+ (white bars) and Par1–/– (black bars) CFs stimulated with 
25 μg/ml poly I:C with or without 200 μM agonist peptide for 8 hours. 10 μM SB203580 was added 30 minutes prior to poly I:C stimulation. (D) 
Effect of MMP or PAR-1 inhibition during poly I:C stimulation of Par1+/+ CFs. The pan-MMP inhibitor GM6001 (GM; 1 μM), the MMP13 inhibitor 
WAY170523 (WAY; 1 μM), or the PAR-1 antagonist SCH79797 (SCH; 250 nM) were added 30 minutes prior to poly I:C stimulation. Data (mean 
± SEM; n = 3–9 independent experiments) were analyzed by 1-way (A and D) or 2-way (C) ANOVA. *P < 0.05; #P < 0.05 vs. unstimulated control 
within the same genotype; †P < 0.05 versus poly I:C alone within the same genotype.
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Discussion
In this study, we found that Par1–/– mice were more susceptible 
to infection with the ssRNA viruses CVB3 and influenza A com-
pared with Par1+/+ mice. Par1–/– mice exhibited reduced IFN-β 
and CXCL10 expression in the heart early after CVB3 infection, 
which likely explains the increased viral load in the heart at 
8 dpi. The higher amount of CVB3 virus in Par1–/– mice was 
associated with increased levels of inflammatory cells, increased 
expression of cytokine mRNAs, and increased cardiac injury 
compared with Par1+/+ mice. Although Par1–/– mice had higher 
levels of virus during the acute phase of CVB3 infection, they 
were able to eliminate the virus by 28 dpi, which indicates that 
they had a normal adaptive immune response. Our results are 
consistent with a prior study showing that TLR3 deficiency 
reduces the innate immune response to CVB3 infection with-
out affecting the adaptive immune response (74). We also found 
that Par1–/– mice had reduced CXCL10 expression in the lung 
after H1N1/PR8 infection, which was associated with increased 
amounts of virus and expression of inflammatory mediators 
compared with infected Par1+/+ mice. These results indicate that 
PAR-1 plays a role in the innate immune response to 2 different 
ssRNA viruses.
In viral myocarditis, NK cells infiltrate the heart first and limit 
viral replication (75). Tlr3–/– and Trif–/– mice both exhibited less 
inflammatory cell infiltrates in their hearts at 3 dpi (48, 76). In a 
heart transplantation model, PAR-1 deficiency was associated with 
reduced recruitment of NK cells and immune cells into the heart 
(77). Consistent with this observation, we found reduced levels of 
Nk1.1 mRNA expression, which is expressed by NK cells, in the 
hearts of Par1–/– mice after CVB3 infection compared with Par1+/+ 
controls. These results suggest that the increased viral titers in the 
hearts of Par1–/– mice is due to a defect in early expression of the 
IFN-β/CXCL10 antiviral pathway and the recruitment of NK cells. 
Thrombin stimulation of NK cells has been shown to increase 
their cell-mediated cytotoxicity (78). Consistent with this observa-
tion, we found that a PAR-1 agonist peptide increased the cyto-
toxic activity of Par1+/+ NK cells, but not Par1–/– NK cells, within 
the splenocyte population (data not shown). This result indicates 
that PAR-1 also contributes to the cytotoxicity of NK cells.
BM transplantation experiments revealed that nonhemato-
poietic cells were the major source of PAR-1 contributing to the 
antiviral response after CVB3 infection. Furthermore, mice with 
cardiomyocyte-specific overexpression of PAR-1 were protected 
against CVB3 infection compared with WT littermate controls. 
In vitro experiments with CFs showed that activation of PAR-1 
enhanced poly I:C activation of p38 and expression of IFN-β and 
CXCL10. Consistent with a role for p38 in the expression of the 
IFN-β/CXCL10 pathway, we found that inhibition of p38 reduced 
induction of both Ifnb1 mRNA and CXCL10 in CFs stimulated 
with both agonist peptide and poly I:C. Taken together, our results 
indicate that PAR-1 contributes to the expression of antiviral genes 
in CFs and that there is cooperative signaling between PAR-1 and 
TLR3. This supports the notion of a dual-sensor system, in which 
an infection is detected by TLRs recognizing PAMPs and PARs 
being activated by proteases generated by the clotting cascade and 
other systems (58). Interestingly, we have observed substantially 
reduced CVB3-induced myocarditis in Par2–/– compared with WT 
mice (A. Weithäuser, S. Antoniak, N. Mackman, and U. Rauch, 
unpublished observations). These results indicate that there are 
specific interactions between different PARs and TLRs in response 
to CVB3 infection.
Viral infections induce TF expression and activate coagula-
tion (12–15). Previously, we found that CVB3 infection of mice 
increased TF protein expression in the heart and increased fibrin 
deposition (14). In addition, the TLR3 agonist poly I:C has been 
shown to induce TF expression in endothelial cells and activate 
coagulation in mice (17). In this study, we observed an increase in 
the levels of Tf mRNA in the liver and heart, as well as TAT com-
plexes in the plasma, at 8 dpi. Fibrin was deposited in areas of the 
myocardium adjacent to inflammatory cell infiltrates. Impor-
tantly, we also found that inhibition of either TF or thrombin 
in WT mice increased CVB3-induced myocarditis. These results 
suggest that virus activation of the TF/thrombin/PAR-1 pathway 
contributes to activation of the innate immune system. Surpris-
ingly, inhibition of thrombin in Par1–/– mice decreased levels of 
CVB3 virus and cardiac injury. One possible explanation for these 
results is that coating of virally infected cells with fibrin may inter-
fere with the clearance of these cells by NK cells. Indeed, fibrin has 
previously been shown to increase the metastasis of tumor cells by 
impeding NK cell killing (79).
It is notable that a deficiency of PAR-1 was associated with sig-
nificantly higher levels of CVB3-induced myocarditis compared 
with either TF or thrombin inhibition in WT mice. This sug-
gests that there may be other protease activators of PAR-1 that 
are generated during CVB3 infection. MMPs represent likely 
candidates. Several studies showed that the MMPs are required 
for early virus clearance in myocarditis (80). For example, a defi-
ciency of MMP9 was associated with increased CVB3 virus load 
and inflammation at 9 dpi due to early impaired innate immune 
response (81). Our in vitro studies revealed that poly I:C stimula-
tion of Par1–/– CFs produced less CXCL10 than Par1+/+ cells. We 
found that poly I:C–stimulated mouse CFs released MMPs that 
activated PAR-1 and increased CXCL10 expression. This is con-
sistent with our recent study showing that isoproterenol-stim-
ulated rat CFs express MMPs that activate PAR-1 (71). Further-
more, we found that administration of the MMP13 inhibitor 
Figure 10
Role of PAR-1 in influenza A infection. Levels of CXCL10 protein (A) 
and H1N1/PR8 genomes (B) in the lungs and of inflammatory media-
tors in BAL (C–F) of H1N1/PR8 influenza A–infected Par1+/+ (white 
bars) and Par1–/– (black bars) mice at 3 dpi. Data are mean ± SEM 
(n = 5–6). *P < 0.05, 2-tailed Student’s t test. 
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WAY170523 (7.5 mg/kg i.p.) once daily significantly increased 
levels of CVB3 in the hearts of WT mice compared with levels in 
mice receiving vehicle (0.0238 ± 0.0054 versus 0.0076 ± 0.0023 
CVB3 genomes normalized to 18S rRNA; n = 6–10; P < 0.05). 
Therefore, both thrombin and MMPs may activate PAR-1 in the 
heart during CVB3 infection.
Our results revealed an unexpected protective role for the TF/
thrombin/PAR-1 pathway during infection of mice with 2 ssRNA 
viruses. Clinically, the direct thrombin inhibitor dabigatran 
etexilate (Pradaxa) is approved for the prevention of blood clots 
and stroke in patients with atrial fibrillation (82), and a selective 
PAR-1 inhibitor, vorapaxar, has been developed as a novel anti-
platelet drug (83, 84). To date, there are no reports of increased 
rates of viral infection in patients receiving Pradaxa (http://www.
pradaxapro.com/safety.jsp) or in patients receiving vorapaxar (83, 
84). Nevertheless, our study raises the possibility that inhibitors 
of thrombin or PAR-1 may increase the risk and severity of viral 
infection in patients.
Methods
Materials. The following cell culture grade reagents were used: poly I:C 
(Sigma-Aldrich); PAR-1 agonist peptide (TFLLR-NH2; Abgent); recombi-
nant murine IFN-β (ProSpec); MDC (Sigma-Aldrich); chloroquine (Invi-
vogen); BX795 (Invivogen); PD98059 (Cell Signaling); SB203580 (Cell 
Signaling). The pan-MMP inhibitor GM6001 was purchased from Cal-
biochem (71). The specific MMP13 inhibitor WAY170523 and the PAR-1 
antagonist SCH79797 were purchased from Tocris Bioscience (71). For 
Western blot analysis, we used specific antibodies against phosphorylated 
p38 and total p38 (Cell Signaling), phosphorylated STAT1 (Abcam), and 
GAPDH (Santa Cruz Biotechnology).
Mice. Par1+/+ and Par1−/− mice were backcrossed 11 generations onto a 
C57BL/6J background, and then Par1+/+ and Par1–/– lines were generated 
and maintained by cousin breeding (85). Male mice were used for all experi-
ments. αMHCPAR-1 mice on a C57BL/6J background overexpress PAR-1 
on cardiomyocytes from the αMHC promoter and have been described 
previously (36).
Virus infection. CVB3 was from the cardiotropic Nancy strain. Virus 
stocks were isolated as described previously (86). Mice were infected at 6–8 
weeks of age i.p. Whereas 10% of Par1–/– mice died after infection, none 
of the Par1+/+ mice died. We used the mouse-adapted strain of influenza 
A (H1N1/PR8; ATCC). The virus was propagated in the allantoic fluid of 
10-day-old fertilized hen eggs, and viral titer was determined by hemagglu-
tination assay (87). For virus inoculation, mice were anesthetized with an 
i.p. injection of a ketamine/xylazine solution (0.6 and 0.35 mg/kg, respec-
tively) and infected i.n. with H1N1/PR8. Previous studies determined that 
this dose of virus is sufficient to elicit an immune response in mice (87).
Quantification of CVB3 titers. HeLa cells (Wisconsin strain; provided by R. 
Rueckert, University of Wisconsin–Madison, Madison, Wisconsin, USA) 
were plated in 96-well plates. Weighed heart samples were homogenized in 
minimum essential media, frozen and thawed 5 times, and centrifuged at 
9,300 g for 10 minutes at 4°C. The supernatant was collected and filtered. 
Serial 10-fold dilutions of the supernatant were added to HeLa cell plates 
in replicates of 6. Virus titers were determined by counting plaques after 
2–3 days of incubation (48).
Histology. Hearts were either snap frozen and embedded in Tissue-Tek 
OCT compound (Dako) or fixed in 4% PFA and embedded in paraffin 
(Sigma-Aldrich). Sections from paraffin-embedded tissues were stained 
with H&E. Tissue-Tek– or paraffin-embedded sections were washed with 
PBS, treated with 4% H2O2, and incubated in a humidified chamber with 
primary antibodies against CD3 (1:75; Santa Cruz Biotechnologies), CD68 
(1:500; Abcam), or fibrin(ogen) (59D8, 1:1,000; gift of M. Runge, Univer-
sity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA). 
Slides were then washed, incubated with the appropriate biotinylated sec-
ondary antibody (Dako), and counterstained with hematoxylin (Merck). 
The Vecastatin ABC Kit (Vector Laboratories) was used to detect the biotin-
tagged secondary antibody (14). Images were taken with a 3CCD Donpisha 
Color Vision Camera attached to a Leica DM RBE microscope (original 
magnification, ×200; Leica Microsystems), and staining was quantified 
with Lucia software (Bensheim).
Echocardiology. Echocardiography was performed using a VisualSonics 
Vevo 660 ultrasound system as described previously (88). LV and LV wall 
dimensions at the end of systole and diastole were measured digitally on 
M-mode tracings and averaged from 4 cardiac cycles. FS was calculated 
from measured ventricle dimensions (36).
Measurement of plasma cardiac troponin I and TAT complexes. Blood was col-
lected from the inferior vena cava into the anticoagulant sodium citrate 
(final concentration, 0.38%) and centrifuged (4,500 g for 15 minutes at 
4°C) to obtain plasma, which was stored at –80°C until analysis. Cardiac 
injury was assessed by measuring plasma levels of cardiac troponin I from 
control and infected mice using a highly sensitive mouse cardiac troponin 
I ELISA kit (Life Diagnostics). Plasma TAT levels were quantified by ELISA 
(TAT Enzygnost Micro Kit; Dade Behring/Siemens).
Measurement of CVB3 and influenza A genomes and cytokine mRNA levels in 
tissues. Total RNA was prepared from heart, liver, and lung and reverse 
transcribed into cDNA as previously described (88). Levels of differ-
ent mRNAs were analyzed by real-time PCR using iTaq Fast Super-
mix (Bio-Rad) and realplex2 Mastercycler (Eppendorf AG). Amplifi-
cation of 18S rRNA was used to correct for input RNA level variation 
and reaction efficiency. Levels of different mRNAs were measured 
using the following TaqMan probe sets from Applied Biosystems: 18S 
(4310893E); Il1b (Mm01336189_m1); Il6 (Mm99999064_m1); Ifnb1 
(Mm00439552_s1); Tnfa (Mm00443259_g1); Par1 (Mm00438851_m1). 
For detection of Nk1.1 mRNA and of CVB3 and H1N1/PR8 genomes, 
we used the following probe sets from Integrated DNA Technologies: 
Nk1.1 forward, 5′-ACTAAACCATGAAACCCCGAG-3′; Nk1.1 reverse, 
5′-AGTGCTTTCAGAGTCCATGTG-3′; Nk1.1 probe, 5′-FAM-ACTCCT-
GACTGCGAATCCCATCC-TAMRA-3′; CVB3 forward, 5′-CCCTGAAT-
GCGGCTAATCC-3′; CVB3 reverse, 5′-ATTGTCACCATAAGCAGC-
CA-3′; CVB3 probe, 5′-FAM-TGCAGCGGAACCG-TAMRA-3′; H1N1/
PR8 forward, 5′-GGACTGCAGCGTAGACGCTT-3′; H1N1/PR8 reverse, 
5′-CATCCTGTTGTATATGAGGCCCAT-3′; H1N1/PR8 probe, 5′-FAM-
CTCAGTTATTCTGCTGGTGCACTTGCCA-TAMRA-3′.
Measurement of cytokines and chemokines. Tissue samples were generated 
and BAL fluid collected as described previously (14, 89). Protein concen-
trations of TNF-α, IL-1β, CXCL1, macrophage-inflammatory protein–2 
(MIP-2), and CXCL10 were measured using commercial ELISAs (Duo-Set; 
R&D Systems).
BM transplantation. Recipient mice (4 weeks old) were irradiated with 13 
Gy (2 doses of 6.5 Gy, 4 hours apart) using a cesium 137 irradiator (JL 
Shepherd) to ablate endogenous BM–derived cells. Irradiated mice were 
injected via the retro-orbital sinus with 2 × 106 BM cells isolated from 
donor animals as described previously (90). Mice were allowed to recover 
for 4 weeks before CVB3 infection.
Isolation of embryonic CFs. Hearts of Par1+/+ or Par1–/– embryos (E14) 
were aseptically isolated and digested overnight in 0.05% trypsin/EDTA 
(Sigma-Aldrich). The next day, digested heart tissue was resuspended 
and plated in DMEM-H media (Gibco) containing 10% FBS, 1% peni-
cillin/streptomycin, and l-glutamine (Cellgro) for 2 hours to allow for 
adherence of fibroblasts (91). Nonadherent cells were discarded, and the 
enriched fibroblast population was cultured for 7 days. CFs were plat-
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Behring/Siemens) on a Start 4 machine (Diagnostica Stago). For inhibi-
tion of MMP13, WT mice were injected i.p. with the MMP13 inhibitor 
WAY170523 (7.5 mg/kg) once daily (71).
Statistics. All statistical analyses were performed using GraphPad Prism 
(version 5.0; GraphPad Software Inc.) or SAS (version 9.2; SAS). Data are 
represented as mean ± SEM. For 2-group comparison of continuous data, 
2-tailed Student’s t test was used. For multiple-group comparison, nor-
mally distributed data were analyzed by 1- or 2-way ANOVA and were Bon-
ferroni corrected for repeated measures over time. A P value less than 0.05 
was considered significant. Linear mixed models with a random intercept 
were used to determine whether significant differences exist between p38 
phosphorylation in stimulated Par1+/+ and Par1–/– CFs over time. The P 
value for the group effect was calculated using a likelihood ratio test.
Study approval. All mouse studies were performed in accordance with 
the guidelines of the IACUC of UNC-Chapel Hill and complied with 
NIH guidelines.
Note added in proof. After the completion of this work, Khoufache 
and colleagues reported that PAR1 contributed to inflammation 
after infection of mice with H1N1 (94). The majority of these stud-
ies used an agonist peptide to stimulate PAR1 and an antagonist 
to inhibit PAR1 in WT mice. However, the authors also found 
that Par1–/– mice were protected from virus infection compared 
with WT mice. These results contrast with our studies showing 
that Par1–/– mice exhibited more inflammation that WT mice after 
infection with H1N1. Additional studies are required to resolve 
these differences, and it seems premature to propose the use of 
PAR1 antagonists for the treatment of influenza.
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ed into wells of a 24-well plate (1.5 × 105 cells/well) and stimulated the 
next day in serum-free media with poly I:C (25 μg/ml), IFN-β (125 ng/
ml), and/or agonist peptide (200 μM). We observed reduced numbers of 
Par1–/– cells compared with Par1+/+ cells, which may be due to reduced 
growth (34). TLR3 signaling was inhibited by incubating cells with MDC 
(60 μM), chloroquine (100 μM), or BX795 (1 μM) (41, 92, 93). Cells were 
also preincubated for 30 minutes with PD98059 (10 μM) or SB203580 
(10 μM) to inhibit activation of MEK1 or p38 MAPKs, respectively (69). 
To inhibit MMP activity or PAR-1, WT cells were incubated 30 minutes 
prior poly I:C stimulation with GM6001 (1 μM), WAY170523 (1 μM), or 
SCH79797 (250 nM) (71).
HEK-293 transfection studies. HEK-293 cells transfected with a stable 
human TLR3-HA tag (pUNO-hTLR3-HA plasmid; Invivogen) were grown 
to 70% confluence and transfected with a pNiFty2-IFB-SEAP plasmid 
(containing the Ifnb1 promoter) with Zeocin selection (Invivogen) using 
Lipofectamine 2000 (Invitrogen). Briefly, cells were cotransfected under 
antibiotic-free conditions in 12-well plates for 6 hours and then washed, 
after which growth media was added. After 24 hours, cells were selected 
using Zeocin (100 μg/ml; Invivogen) for an additional 24 hours. Cells 
were washed and then incubated with fresh growth media, either alone or 
with agonist peptide (100 or 200 μM) and/or poly I:C (25 μg/ml), for an 
additional 24 hours. Media was collected, and SEAP was detected using 
QUANTI-blue (Invivogen), black well plates, and a SpectraMax M5 plate 
reader (640 nm).
Western blot analysis. Cell lysates were resuspended in 6× Laemmli sample 
buffer, boiled for 5 minutes, and then applied to 4%–15% Tris-Glycine gels 
(Bio-Rad Laboratories) to separate proteins using electrophoresis. Proteins 
were transferred to PVDF membranes (Millipore), and membranes were 
blocked for 1 hour with Odyssey blocking buffer (LI-COR Biosciences). 
Primary antibodies against phosphorylated p38 (1:1,000 dilution), non-
phosphorylated p38 (1:1,000 dilution), phosphorylated STAT1 (1:1,000 
dilution), and GAPDH (1:10,000 dilution) were incubated overnight at 
4°C. Washed membranes were incubated with fluorescence-labeled sec-
ondary antibodies (1:10,000 dilution) for 1 hour. Membranes were then 
washed 3 times and analyzed using an Odyssey Infrared Imaging System 
(LI-COR Biosciences).
Inhibition of TF, thrombin, or MMP13 in mice. For inhibition of TF, 
WT mice received i.p. injections of the rat anti-mouse TF monoclonal 
antibody 1H1 (20 mg/kg) or an isotype control (rat IgG2a, 20 mg/kg; 
Sigma-Aldrich) (90). For inhibition of thrombin, WT mice were fed 
custom-made AIN-93M chow diets containing peanut flavoring (2 g/kg 
chow) with or without dabigatran etexilate (10 g/kg chow) (Dyets Inc.). 
30% of mice treated with dabigatran etexilate exhibited signs of gastro-
intestinal bleeding, and death rates for Par1+/+ and Par1–/– mice were 10% 
and 30%, respectively. aPTT was measured using the Actin FS kit (Dade 
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